Protocol Name: ZENITH: Zilebesiran in Patients with HTN not Adequately Controlled and with either Established CVD or at High Risk for CVD
Protocol #: ALN-AGT01-008
Indication: HTN (Uncontrolled)
GFR: <60
Principal Investigator: Ankit N. Mehta, MD, FASN
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246